| Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel-Carboplatin Chemotherapy? A Retrospective Study. | |
| | |
MedLine Citation:
|
PMID: 23154549 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
INTRODUCTION: : Early prediction of the efficacy of a combination of an antiangiogenic drug with cytotoxic chemotherapy is a significant challenge. In that regard, circulating endothelial cells (CECs) and cytokeratins (CKs) seem to reflect their roles in both tumor angiogenesis and tumor cell death. METHODS: : Patients with advanced, previously untreated non-small-cell lung cancer were randomly assigned to an endostatin treatment group (paclitaxel + carboplatin + endostatin) and a control group (paclitaxel + carboplatin + placebo). A total of 122 patients were evaluated, of whom 107 had measurements of blood CECs, CK8, caspase-cleaved CK18 (ccCK18), and uncleaved CK18 (CK18) before and at weeks 3 and 6 of treatment, respectively. RESULTS: : Higher baseline CECs in patients with a tumor response (partial remission + stable disease, p = 0.002 for the entire group; p = 0.000 for the treatment group) were observed. The number of CECs decreased significantly after endostatin treatment (p = 0.000), whereas CK levels increased. Increased levels of ccCK18 and CK18, but not CK8, reached significance (p = 0.001 and p = 0.048, respectively) when compared with the baseline. Tumor response showed a strong correlation with reduction of CECs (p = 0.000) and increase of ccCK18 (p = 0.040) after endostatin therapy. Cutoff values of changes of CECs and ccCK18 for prediction of survival were 0.58/μl and 19.6 ng/ml, respectively. Reduction of CECs and increase of ccCK18 significantly correlated with longer median survival (p = 0.013 and p = 0.016 for progression-free survival; p = 0.009 and p = 0.012 for overall survival, respectively). CONCLUSIONS: : CECs and CKs could be biomarkers for selecting patients with non-small-cell lung cancer who will benefit from treatment with endostatin in combination with paclitaxel plus carboplatin. |
| | |
Authors:
|
Tian-Qing Chu; Hao Ding; David H Garfield; Ai-Qin Gu; Jun Pei; Wei-Dong Du; Bao-Hui Han |
Related Documents
:
|
8774919 - Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to ... 23295799 - Palliative radiation therapy practice in patients with metastatic non-small-cell lung c... 23542459 - Early-stage pulmonary adenocarcinoma (t1n0m0): a clinical, radiological, surgical, and ... 8410109 - A prospective phase ii study on photodynamic therapy with photofrin ii for centrally lo... 23545279 - Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced... 2244019 - The importance of vocal cord mobility in t2 laryngeal cancer. 7462019 - Carcinoembryonic antigen in the assessment of lung cancer. 19470929 - Improved survival in metastatic colorectal cancer is associated with adoption of hepati... 9824999 - Comparison of two different radiotherapy schedules for spinal cord compression in prost... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Volume: 7 ISSN: 1556-1380 ISO Abbreviation: J Thorac Oncol Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-11-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101274235 Medline TA: J Thorac Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 1781-9 Citation Subset: IM |
Affiliation:
|
*Department of Pulmonology, Shanghai Chest Hospital, Jiaotong University, Shanghai, China; †Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital, Fudan University, Shanghai, China; ‡Medical Department, Pro-Med Cancer Centers, Shanghai, China; and §Division of Surgical Oncology and Thoracic Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: FGFR1 Amplification in Squamous Cell Carcinoma of The Lung.
Next Document: Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contributi...